Plasma Biomarkers and Disease Prognosis in Mild Cognitive Impairment with Lewy Bodies

IF 7.4 1区医学 Q1 CLINICAL NEUROLOGY

Movement Disorders Pub Date : 2025-03-31 DOI:10.1002/mds.30181

Paul C. Donaghy, Jahfer Hasoon, Calum A. Hamilton, Joanna Ciafone, Rory Durcan, Nicola Barnett, Kirsty Olsen, Sarah Lawley, Gemma Greenfinch, Michael Firbank, Amanda Heslegrave, Henrik Zetterberg, Louise Allan, John T. O'Brien, John‐Paul Taylor, Alan J. Thomas

{"title":"Plasma Biomarkers and Disease Prognosis in Mild Cognitive Impairment with Lewy Bodies","authors":"Paul C. Donaghy, Jahfer Hasoon, Calum A. Hamilton, Joanna Ciafone, Rory Durcan, Nicola Barnett, Kirsty Olsen, Sarah Lawley, Gemma Greenfinch, Michael Firbank, Amanda Heslegrave, Henrik Zetterberg, Louise Allan, John T. O'Brien, John‐Paul Taylor, Alan J. Thomas","doi":"10.1002/mds.30181","DOIUrl":null,"url":null,"abstract":"BackgroundLittle is known about the prognostic value of plasma biomarkers in mild cognitive impairment with Lewy bodies (MCI‐LB).ObjectivesTo investigate the association of four plasma biomarkers with disease progression in MCI.MethodsPlasma amyloid‐beta (Aβ)42/40, glial fibrillary acidic protein (GFAP), neurofilament light (NfL), and phosphorylated tau 181 (pTau181) were measured at baseline in a longitudinal MCI cohort (n = 131).ResultsBaseline plasma NfL was associated with increased risk of dementia/death in the entire cohort. In MCI‐LB, baseline plasma NfL, GFAP, and pTau181 were associated with increased risk of dementia/death and increased cognitive decline measured by the Addenbrooke's Cognitive Examination‐Revised.ConclusionspTau181, GFAP, and NfL are associated with more rapid disease progression in MCI‐LB and, with further validation, could be useful to support prognosis and stratification for clinical practice and treatment trials. Further work, including clinicopathological studies, is needed to understand the biological correlates of these markers in MCI‐LB. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.","PeriodicalId":213,"journal":{"name":"Movement Disorders","volume":"72 1","pages":""},"PeriodicalIF":7.4000,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Movement Disorders","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/mds.30181","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

BackgroundLittle is known about the prognostic value of plasma biomarkers in mild cognitive impairment with Lewy bodies (MCI‐LB).ObjectivesTo investigate the association of four plasma biomarkers with disease progression in MCI.MethodsPlasma amyloid‐beta (Aβ)42/40, glial fibrillary acidic protein (GFAP), neurofilament light (NfL), and phosphorylated tau 181 (pTau181) were measured at baseline in a longitudinal MCI cohort (n = 131).ResultsBaseline plasma NfL was associated with increased risk of dementia/death in the entire cohort. In MCI‐LB, baseline plasma NfL, GFAP, and pTau181 were associated with increased risk of dementia/death and increased cognitive decline measured by the Addenbrooke's Cognitive Examination‐Revised.ConclusionspTau181, GFAP, and NfL are associated with more rapid disease progression in MCI‐LB and, with further validation, could be useful to support prognosis and stratification for clinical practice and treatment trials. Further work, including clinicopathological studies, is needed to understand the biological correlates of these markers in MCI‐LB. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Movement Disorders 医学-临床神经学

CiteScore

13.30

自引率

8.10%

发文量

371

审稿时长

12 months

期刊介绍： Movement Disorders publishes a variety of content types including Reviews, Viewpoints, Full Length Articles, Historical Reports, Brief Reports, and Letters. The journal considers original manuscripts on topics related to the diagnosis, therapeutics, pharmacology, biochemistry, physiology, etiology, genetics, and epidemiology of movement disorders. Appropriate topics include Parkinsonism, Chorea, Tremors, Dystonia, Myoclonus, Tics, Tardive Dyskinesia, Spasticity, and Ataxia.